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and 9%, respectively. Compared with placebo, more patients achieved HbA1c
7% (39.4% vs 24.4%) and 8% (79.5% vs 60.6%) and fewer patients remained at or
worsened to HbA1c 9% (4.2% vs 13.9%) with dapagliflozin. CONCLUSIONS: Dapa-
gliflozin 10 mg/day reduced HbA1c across all baseline HbA1c categories; greater
reductions were seen in patients with higher baseline HbA1c. Substantially more
patients attained HEDIS HbA1c categories of7% and8% and substantially fewer
patients remained at orworsened toHbA1c9%with dapagliflozin, comparedwith
placebo. Collectively, dapagliflozin provided better glycemic control than placebo
over a range of HbA1c levels.
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OBJECTIVES: To evaluate the long-term clinical and economic consequences of
saxagliptin in comparison with sulphonylurea available in the Russian market.
METHODS: The analysis is based on the Cardiff Long Term Model (Clarke et al.
2004). Three scenarios were developed and tested. Scenario 1 “trial based scenario”
(S1) the active treatment is saxagliptin (Onglyza®) added to metformin (MET),
which is compared to MET plus sulphonylurea (SU); input data are derived from
study D1680C00001 (Goke et al. 2010). Scenario 2 “real world scenario” (S2). Efficacy
and safety data taken from study D1680C00001, the cohort was taken from the
Russian Federal Diabetes Patient Register, time horizon was set to 40 years, HbA1c
threshold of 9.0% was assumed. Scenario 3 “MET monotherapy scenario” (S3). Ef-
ficacy and safety data taken from a study of DeFronzo et al. 2009. Patient demo-
graphic characteristics were the same as in Scenario 2; time horizon - nine years as
in the base case scenario 1. The cost-effectiveness analysis was performed from
the government health care system’s perspective. The costs applied were based on
prices listed in the essential drug list (MoH 2010) and official standards of treatment
developed by expert groups at the Ministry of Health level (Russian Federation).
RESULTS: In S1 - MET plus saxagliptin was associated with an incremental cost-
effectiveness ratio (ICER) of Russian Roubles (RUB) 38,840 per QALY gained, and
RUB 7,142,690 per life year gained (LYG) versus SU. In S2 - ICER of RUB 104,153 per
QALY gained and RUB 9,884,121 per life year. In S3 - ICER resulted in RUB 20,353,081
perQALYandRUB 29,044,346 per life year gained.CONCLUSIONS: In both scenarios
(1 and 2), assuming a willingness to pay threshold of RUB 800’000, saxagliptin
would be considered cost-effective in the Russian setting.
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OBJECTIVES: To assess the efficacy and safety of DPP-4 inhibitors, including sita-
gliptin, saxagliptin, vildagliptin and linagliptin, in type 2 diabetic patients.
METHODS: Both published and unpublished randomized controlled trials (RCTs)
for type 2 diabetic patients were selected if they: 1) compared DPP-4 inhibitors with
either placebo or another hypoglycemic; 2) had study duration of  12 weeks; and
3) had at least one baseline and post-treatment efficacy and/or safety outcome.
RESULTS: A total of 62 articles met the inclusion criteria. Seven of these trials
involved Japanese patients, but inclusion resulted in significant heterogeneity (I2
82%). Exclusion of these 7 trials resulted in a reduction of heterogeneity (I259%)
with a more stable pooled effect size. Analyses of the non-Japanese studeis (n55
RCTs) indicated that, compared to placebo, DPP-4 inhibitors were associatedwith a
reduction in hemoglobin (Hb) A1c (weightedmean difference (WMD) -0.65%; 95%
CI, -0.71 to -0.60) but a higher risk of hypoglycemia (Odds ratio (OR)  1.30; 95% CI,
1.01 to 1.68). A separate analysis of the 7 Japanese studies showed that, compared
to placebo, DPP-4 inhibitorswere associatedwith a greater reduction inHbA1c than
non-Japanese patients (WMD -1.67%; 95% CI, -1.89 to -1.44; P 0.05) and a non-
significant increase in risk of hypoglycemia (OR, 1.41; 95% CI, 0.51 to 3.88). When
comparing DPP-4 inhibitors to active comparators, the I2 was still high after sepa-
rating out Japanese studies. In the 17 active comparator trials, there was no signif-
icant difference in HbA1c reduction (WMD 0.04%; 95% CI, -0.09 to 0.16) or risk of
hypoglycemia (OR 0.60; 95% CI, 0.22 to 1.61) for DPP-4 inhibitors compared to
other anti-diabetic medications. CONCLUSIONS: Differences in efficacy and safety
were observed between Japanese and non-Japanese patients. The extent of HbA1c
reduction was more than doubled in trials including Japanese populations com-
pared to non-Japanese populations.
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OBJECTIVES: To evaluate, in a US managed care setting, health outcomes among
patients with type 2 diabetes mellitus (T2DM) initiating basal insulin therapy via
disposable penwith insulin glargine (GLA-P) or insulin detemir (DET-P).METHODS:
Using the claim database from a US health plan (InVision™), T2DM patients initi-
ating GLA-P or DET-P were included if they were18 years, had continuous health
plan coverage for 6months before (baseline) and 1-year after initiation (follow-up),
with 1 prescription for oral antidiabetic drugs (OADs) and/or exenatide, but no
insulin use, during baseline. To minimize selection bias, stringent 1:1 propensity
score matching was used to balance baseline characteristics of the two cohorts.
Outcomesmeasures included 1-year treatment persistence and adherence, hemo-
globin A1c (A1C), hypoglycemia-related events, healthcare utilization and costs.
RESULTS: A totla of 5828 matched patients were included (n2914 in each cohort;
female 44.4%, baselinemean age 54.4 years; Charlson comorbidity index 0.55; num-
ber of OADs 2.60). During 1-year follow-up, patients initiating GLA-P, compared
with DET-P, were more persistent (58.8 vs. 44.1%, P0.001) and adherent (adjusted
medication possession ratio 0.68 vs. 0.66, P0.002) with treatment, had lower daily
insulin doses (DACON) (29.2 vs. 32.5 units/day, P0.012), similar rates of hypogly-
cemia-related events (5.9 vs. 6.6%, P0.281), lower diabetes prescription costs
(mean $3,142 vs. $3,372, P0.043) and marginally lower total health care costs
(mean $30,364 vs. $33,109, P0.086). Among patients with A1C data available
(GLA-P n356, DET-P n332), A1C at 1-year follow-up was 8.14% in GLA-P vs. 8.50%
in DET-P (P0.007), reflecting A1C reduction from baseline of 1.03 vs.0.86%
(P0.260). CONCLUSIONS: This real-world comparative study suggested that
among T2DM patients initiating basal analog insulins using disposable pen, com-
paredwithDET-P, GLA-Pmight be associatedwith increased treatment persistence
and adherence, similar rates of hypoglycemia, lower DACON and healthcare costs
during 1-year follow-up. This, however, should be confirmed in future pragmatic
randomized clinical trials.
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OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin re-
ceptor blockers (ARBs) are recommended to reduce albuminuria, a risk factor for
nephropathy and all-cause mortality. The objective of the study was to compare
ACEIs and ARBs for development of end-stage renal disease (ESRD) development
and all-cause mortality in veteran patients with type 2 diabetes. METHODS: This
was a retrospective cohort study utilizing data in years 2002-2007 from the national
Department of Veterans Affairs (VA) databases. To be included in the sample pa-
tients had to be newly-diagnosed, new users of ACEIs or ARBs, and have a baseline
measure of albuminuria. Multivariate logistic regression models that assessed ef-
fect of ACEIs and ARBs on ESRD and all-cause mortality were estimated with con-
trols for risk factors of ESRD and all-causemortality, Elixhauser comorbidities, and
location of care. Propensity scores were used to adjust for differences in baseline
characteristics between ACEI and ARB patients. RESULTS:A total of 20,876 patients
using ACEIs (n18,947) or ARBs (n1929) met inclusion criteria. Mean follow-up
was two years. No significant differences were found between ACEIs and ARBs for
ESRD (1.12 [95% CI0.19-6.72]) and all-cause mortality (0.86 [95% CI0.24-3.07]).
Some comorbidities, however, had higher adjusted odds for ESRD (liver disease
odds ratio 7.40 [95% CI2.91-18.87]; fluid and electrolyte disorders odds ratio 7.71
[95% CI3.46-17.17]; deficiency anemias odds ratio 5.81 [95% CI2.40-14.09]) or
all-cause mortality (history of myocardial infarction odds ratio 2.85 [95% CI1.26-
6.46]), underlining the importance of prevention of these conditions.
CONCLUSIONS: There were no significant differences in ESRD and all-cause mor-
tality betweenACEIs and ARBs in this study that included patients from every state
in the United States, the District of Columbia, and Puerto Rico. Additionally, this
study shows that clinicians should focus educational efforts on disease prevention
due to downstream effects of certain conditions in patients with type 2 diabetes.
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OBJECTIVES: Turner syndrome (TS) is a chromosomal disorder that has total or
partial absence of chromosome X and haploinsufficiency of the SHOX gene. Fur-
thermore, it is associated with short stature with particular phenotype and hypo-
gonadism. Several studies have shown that the use of recombinant human growth
hormone (GH) in girls with TS raises final height. The aim of this study was to
describe the characteristics of a cohort of girls with TS diagnosed and treated with
GH in Colombia.METHODS: A cohort of 22 girls with TS, who entered to the drug-
international epidemiological record (KIGS) between 2004 and 2010were tracked in
Colombia. Girlswere diagnosedwith short stature and treatedwithGH therapy and
followed-up for 2 years. Tracking measures were: the time of starting therapy,
treatment regimens and clinical outcomes were estimated in terms of height mea-
sured by standard deviation units (SDS) and velocity growth in cm per year. Cohort
data was compared against literature findings published for girls treated on GH
with TS (Ranke MB et al 1988) and girls without GH treatment and TS (Tanner JM et
al 1976). RESULTS: Girls started GH therapy at a mean age of 7.03 years with a dose
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of 0.34mg/kg/week; and showed amedian height of 110.0cms (-2.5 SDS (Tanner)) at
baseline. Likewise, girls reached amedian height of 117.1cms (-1.9 SDS (Tanner)) at
the end of the first year and 122.5cms (-1.6 SDS (Tanner)) at the end of the second
year; which represents an improvement of over 20% growth compared to girls with
TS without GH therapy. CONCLUSIONS: Due to an earlier initiation of treatment in
Colombian girls compared to global reported data (at 9.7 years), GH achieved at the
end of first year height increments of 8.6cm for the Colombian cohort vsersus
7.2cm in global cohort.
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Langer J1, Bouchard JR1, Ploug UJ2
1Novo Nordisk, Inc., Princeton, NJ, USA, 2Novo Nordisk A/S, Søborg, Denmark
OBJECTIVES: The ADA/EASD Consensus Panel recommends an individualized
treatment approach for patients with type 2 diabetes (T2DM) based on efficacy,
safety, tolerability, and ease of use. A challenge in the management of T2DM is to
maximize glycemic control while minimizing side effects, such as weight gain and
hypoglycemia. A clinically relevant composite endpoint of HbA1c7%, no weight
gain, and no hypoglycemia may be useful for evaluation of diabetes treatments.
The objective is to estimate the Number Needed to Treat (NNT), using this com-
posite endpoint, across all seven RCTs in T2DM patients in the liraglutide clinical
trial program.METHODS: The findings of a recently conductedmeta-analysis (Zin-
man et al. 2012) from seven trials (N4625) at week 26 in the liraglutide clinical trial
program were used to calculate the NNT to achieve the composite endpoint of
HbA1c7%, no weight gain and no hypoglycemia for liraglutide vs. comparator
therapies and placebo. Logistic regression on the intent-to-treat population using
the last observation carried forward was used. The NNT was calculated as 1/Abso-
lute Risk Reduction (ARR), with ARR being the difference in the percentage of pa-
tients achieving the composite endpoint with liraglutide vs. the comparator ther-
apy or placebo. RESULTS: The calculated NNT values for liraglutide 1.2 mg ranged
from 3.8 (vs. rosiglitazone) to 4.8 (vs. sitagliptin) and from 2.9 (vs. rosiglitazone) to
6.7 (vs. exenatide) for liraglutide 1.8 mg. The NNT across all comparators for lira-
glutide 1.2 mg was 3.8 vs. rosiglitazone, 4.2 vs. glimepiride, 4.2 vs. placebo and 4.8
vs. sitagliptin. For liraglutide 1.8 mg the NNT was 2.9 vs. rosiglitazone, 3.1 vs.
glimepiride, 3.1 vs. placebo, 3.4 vs. sitagliptin, 4.0 vs. insulin glargine and 6.7 vs.
exenatide. CONCLUSIONS:Across the seven phase 3 trials in the liraglutide clinical
trial program, the calculated NNT suggests that liraglutide provides clinically
meaningful benefits in T2DM.
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OBJECTIVES: The present study examined the association between initial mono-
therapy with metformin (MET) or sulfonylurea (SU) and subsequent initiation of
insulin in older patients with type 2 diabetes mellitus (T2DM). METHODS: In a
retrospective cohort study using the GE electronic medical database, eligible pa-
tients with T2DM included those 65 yrs who received their first prescription (Rx)
of SU orMET as initialmonotherapy between 2003 and 2008. The followup lasted to
the end of 2009 or the patient’s latest data available. Insulin initiation was deter-
mined by Rx records. Logistic regression analysis evaluated the likelihood of insu-
lin addition and Cox regression model estimated time to initiation of insulin. Dif-
ferences in baseline characteristics (demographics, clinical and lab measures, and
comorbidities) were controlled for using propensity score matching (PSM).
RESULTS: Overall, 12,036 patients were included in the analysis with 6,018/group.
Mean age was 75 years and 50% were male. While controlling for differences in
baseline characteristics using PSM, patients who initiated with SU had a signifi-
cantly (p0.001) higher incidence of insulin addition (2.8% vs. 1.4%) compared to
those initiated with MET after 1 year of follow up. The likelihood of add-on insulin
usewas higher in patients initiatedwith SU thanwithMET (OR [95%CI] 1.96 [1.51,
2.55]; p0.001). SU was also significantly associated with shorter time to insulin
add-on use compared to MET (HR [95% CI]  2.20 [1.91, 2.52]; p0.001). The rate of
insulin addition remained significantly higher (p0.001) with initial SU mono-
therapy vs. MET after 2 and 3 yrs of follow up (6.1% vs. 2.6%, and 8.1% vs. 3.9%,
respectively). CONCLUSIONS: In a cohort of older patients with T2DM initiating
antihyperglycemic therapy, patients who started with SU monotherapy received
insulin therapy more frequently and earlier than those who started with MET.
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OBJECTIVES: This study evaluated glycemic control after basal insulin initiation
among patients with type II diabetes mellitus (T2DM). METHODS: A retrospective
analysis was conducted using electronic medical records (EMR) from General Elec-
tric (GE) health care. Adult patients with T2DMwho initiated basal insulin between
February 2006 andAugust 2009were selected, and the date of insulin initiationwas
set as the index date. The proportion of patients reaching fasting plasma glucose
(FPG) target (FPG between 70-130 mg/dL) and glycated hemoglobin (HbA1c) target
(HbA1c7%) were reported. Time to reaching FPG and HbA1c targets was assessed,
and Cox proportional hazard models were established to identify associated de-
mographic and clinical factors. RESULTS: A total of 1473 patients (mean age 63.0
years; 51.3% female) were identified. Of them, 12% had baseline HbA1c  6.5, 7%
had 6.5 HbA1c 7, 23% had 7 HbA1c 8, 21% had 8 HbA1c 9, and 37% had
HbA1c  9. A higher proportion of patients reached the FPG target than the HbA1c
target (52% vs. 45%) 12 months after insulin initiation. Patients reached the FPG
target (median: 337 days, 95% confidence interval [CI]: 308-366) sooner than the
HbA1c target (median: 490 days, 95% CI: 400-587). There was a greater variation in
time to reaching the HbA1c target than the FPG target across groups of patients
with different baseline HbA1c values. Baseline HbA1c level was the main factor
influencing the time to reaching FPG or HbA1c target, with higher baseline HbA1c
values associated with longer time to glycemic goal. CONCLUSIONS: About half of
the patients with T2DM reached the glycemic goal after initiating basal insulin.
Patients reached the FPG target sooner than the HbA1c target.
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OBJECTIVES: Acromegaly is a rare, slowly progressing disorder resulting from ex-
cessive growth hormone. It is characterized by skeletal and soft-tissue enlarge-
ment and increased risk of cardiovascular death. Treatmentmay be long-term and
complex, involving medications, surgery, and radiotherapy; and there are limited
published data on treatment patterns. We used a novel graphical technique to
analyze treatment patterns in acromegaly. METHODS: Combining two major US
claims datasets (Thomson Reuters MarketScan and IMS Health PharMetrics), we
identified acromegaly patients first treated between July 1, 2002-December 31,
2009. Patients were followed for 6 months to 3 years, from first treatment until
either end of enrollment or 6/30/10. We analyzed treatment patterns using an
innovative method which produces high-resolution images combining thousands
of individual patient histories. These images used multi-colored line segments to
represent different treatments. Images were reviewed for segment length and
changes in colors to evaluate treatment patterns over time. We compared graphi-
cal results to summary statistics. RESULTS:We identified 2,027 newly treated ac-
romegaly patients. First observed treatment was surgery in 733 patients (36.2%),
pharmacologic therapy in 1203 (59.3%) and radiation in 91 (4.5%). Octreotide acetate
long-acting (LAR) for injection was the first treatment in 173 patients (8.5%). Most
users initiated therapy at 10-20mg/month (n141, 81.5%). Among these, 47 (33.3%)
increased octreotide dose or switched to other treatments in the follow-up period.
Second treatment was octreotide 30mg/month in 39 (83.0%), 40mg/month in 7
(14.9%), and surgery in 1 (2.1%). Graphical analysis revealed patterns of treatment
switching and medication persistence that differed depending on the initial ther-
apy;multiple images from this analysis will be presented.CONCLUSIONS: Invasive
treatments appeared less common than pharmacologic therapy as initial acromeg-
aly treatments. Most octreotide LAR for injection users remained on their initial
therapy without dose or treatment changes during observation. Graphical analysis
provided detailed insights not immediately apparent in summary statistics.
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OBJECTIVES: To validate outcomes from a diabetes model through comparison to
results reported in trials published in the peer-reviewed literature. METHODS:
Diabetes is a debilitating, costly disease that continues to increase in prevalence.
Computer simulation models that estimate the impact of interventions on behalf
of patientswith diabetes are pivotal tools in improving care and evaluating place in
therapy and cost-effectiveness of new treatments. Themodel was developed using
the latest, best available evidence from the literature. It includes a set of compli-
cation submodels, a continuous-time HbA1c model, and a treatment model that
can replicate recently published consensus algorithms. Additionally, the model
incorporates treatment specific adverse events, patient adherence to therapy, and
estimates of the patient population with a durable response. Random sampling
from distributions from trial cohort characteristics is performed to build a patient
profile. Each patient is simulated over the trial timeframe. Complications included:
macrovascular-heart (coronary heart diseasecongestive heart failure), microvas-
cular-stroke, microvascular (renalneuropathyretinopathy), mortality, and
overall complications rates. Scatter plots of the model predicted results versus the
results reported for numerous trial populations in the literature (including 7 stud-
ies from ACCORD, ASPEN, and ADVANCE) were constructed. Linear regression es-
timates were calculated with adjusted correlation coefficients as an estimate of
model validity. RESULTS: The predicted model outcomes were generally accept-
ably accurate as judged by adjusted correlation coefficients (macrovascular-heart,
0.9118; macrovascular-stroke, 0.5388; microvascular, 0.9508; mortality, 0.9808;
overall complications, 0.9334). CONCLUSIONS: The diabetes modeling framework
possesses the necessary flexibility to perform broad population analysis and im-
portant subgroup analyses. The validation exercise, in which the model simulates
published cohorts, adequately predicts observed rates of complications.
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